<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204981</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 17-1899</org_study_id>
    <nct_id>NCT03204981</nct_id>
  </id_info>
  <brief_title>Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias</brief_title>
  <official_title>Intramural Needle Ablation for the Treatment of Refractory Ventricular Arrhythmias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivek Reddy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety and efficacy of intramural needle ablation (INA) in the&#xD;
      treatment of intramural ventricular arrhythmias in patients for whom standard RF ablation has&#xD;
      been unsuccessful. The clinical team hypothesize that the increased current density and&#xD;
      improved rates of transmural lesion creation seen with intramural needle ablation will lead&#xD;
      to successful arrhythmia termination with minimal or no increased risk of complication.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radiofrequency (RF) ablation is the most commonly employed method for the catheter treatment&#xD;
      of cardiac arrhythmias. Myocardial scar serves as the most frequent substrate for the genesis&#xD;
      of both atrial and ventricular arrhythmias. Such scar frequently contains surviving myocyte&#xD;
      bundles interspersed with fibrotic tissue, which leads to slow conduction. Areas of denser&#xD;
      fibrosis cause conduction block. When appropriately arranged, conduction through or around&#xD;
      these scars leads to the creation of a &quot;reentry&quot; circuit through which an arrhythmia is&#xD;
      generated and maintained. Each reentry circuit contains within it an area called the isthmus,&#xD;
      a portion of the circuit located in a position intimately related to the scar border zone.&#xD;
      Electrical activation travels slowly through the isthmus before breaking out into normal&#xD;
      myocardium. Ablation at the site of an isthmus will terminate a reentrant tachycardia.&#xD;
&#xD;
      A variety of techniques, including electroanatomic mapping and activation, entrainment, and&#xD;
      substrate mapping, are employed during electrophysiologic (EP) study to identify areas of&#xD;
      myocardial scar and potential isthmus sites. Points or lines of ablation using RF energy are&#xD;
      then created in an attempt to interrupt the reentry circuit. Typically, RF energy is applied&#xD;
      via a catheter tip electrode to the endocardial or epicardial surface of the heart and&#xD;
      grounded via an electrode pad placed on the patient's skin. RF energy in this setting is&#xD;
      dispersed through the entirety of the tissue between catheter tip and grounding pad. The&#xD;
      standard 7-French, 4-mm tip catheters are highly successful at ablating circuits located&#xD;
      within a few millimeters of the catheter tip. A focal, 1mm area of resistive heating occurs&#xD;
      within the myocardium immediately in contact with the catheter tip; myocardial cell death&#xD;
      occurs several millimeters more deeply through passive, conductive heating, which spreads&#xD;
      outward from the contact point.&#xD;
&#xD;
      While the standard catheter is effective at the ablation of superficial arrhythmias, it has&#xD;
      proven more problematic when used for deep myocardial sites or for creating transmural&#xD;
      lesions. A number of alternatives have been developed in an attempt to access these sites.&#xD;
      8-mm or 10-mm catheter tips are able to create larger zones of resistive heating, delivering&#xD;
      direct RF energy to a larger area of myocardium. A larger interface between catheter tip and&#xD;
      blood improves cooling and allows for the delivery of more power without a rise in&#xD;
      impedance.The clinical use of these larger catheters can, however, be limited by rapid&#xD;
      temperature rises at the catheter-tissue interface, resulting in thrombus formation, char,&#xD;
      and &quot;steam pop&quot; rupture of the endocardial surface. The use of irrigated ablation catheters&#xD;
      have improved upon the ability to deliver RF energy without a sustained rise in impedance.&#xD;
      Both open irrigated- and closed-loop irrigated catheters circulate saline along the catheter&#xD;
      tip-myocardial interface, allowing for continued delivery of RF current without thrombus&#xD;
      formation at the endocardial surface. Intramyocardial temperature rises accordingly without a&#xD;
      concomitant endocardial temperature surge, creating larger and deeper myocardial ablation&#xD;
      zones. Transcoronary ethanol ablation has also been employed with moderate success in&#xD;
      patients with arrhythmias resistant to endocardial catheter ablation.This technology,&#xD;
      however, grants only limited control over the size of the resulting infarct and is restricted&#xD;
      by the need for perfusion of the scar zone by an accessible coronary artery.&#xD;
&#xD;
      Nevertheless, there remain occasions in which an arrhythmia cannot be eliminated by standard&#xD;
      ablation techniques. This is seen most frequently due to deep intramural ventricular&#xD;
      tachycardia, sometimes encountered following myocardial infarction. Both standard and&#xD;
      alternative ablation strategies are frequently either unavailable or inadequate for&#xD;
      termination of these arrhythmias.&#xD;
&#xD;
      Initial experience with an electrically active needle electrode have demonstrated that&#xD;
      radiofrequency ablative energy can effectively create lesions of homogeneous necrosis. Needle&#xD;
      electrodes have been used experimentally from the epicardial surface, from the endocardium ex&#xD;
      vivo and in vivo in an internally irrigated form. It has been shown that the use of a&#xD;
      narrow-gauge non-irrigated endocardial needle ablation catheter creates very narrow but deep&#xD;
      lesions due to the small electrode size. Catheters featuring a retractable needle tipped&#xD;
      electrode with intramyocardial saline infusion have also shown promise as a means of&#xD;
      accessing deep myocardial circuits in ventricular tachycardia ablation.18&#xD;
&#xD;
      The proposed study will further examine the role of INA in patients with ventricular&#xD;
      arrhythmias resistant to standard ablation techniques.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 17, 2017</start_date>
  <completion_date type="Actual">April 20, 2021</completion_date>
  <primary_completion_date type="Actual">April 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with VT and number of participants with PVCs who had freedom from ventricular arrhythmia at 6 months for participants who had ablation performed using the experimental Needle ablation catheter versus standard ablation catheter.&#xD;
Needle - patient had ablation performed using the experimental Needle ablation catheter.&#xD;
Registry - patient had ablation using a standard ablation catheter and did not need additional ablation using the Needle catheter.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Events of Procedural Complications</measure>
    <time_frame>at 6 months</time_frame>
    <description>Number of events of procedural complications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Post-ablation Inducibility</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Termination</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Duration of Intramural Needle Ablation</measure>
    <time_frame>Day 1</time_frame>
    <description>Total duration of intramural needle ablation for patient who had ablation performed using the experimental Needle ablation catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Intramural Needle Ablations</measure>
    <time_frame>Day 1</time_frame>
    <description>Total Number of Intramural Needle Ablations for patient had ablation performed using the experimental Needle ablation catheter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <arm_group>
    <arm_group_label>Intramural Needle Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intramural Needle Ablation</intervention_name>
    <description>The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.</description>
    <arm_group_label>Intramural Needle Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>standard ablation</description>
    <arm_group_label>Intramural Needle Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The study will include patients with any of the following criteria: a) monomorphic&#xD;
             ventricular tachycardia (VT); b) frequent ventricular arrhythmia (defined as unifocal&#xD;
             PVCs, couplets, non-sustained VT) with a PVC burden ≥13%, or is causing a decline in&#xD;
             left ventricular (LV) ejection fraction to &lt;40%; or c) previous failed ablation for&#xD;
             one or more of the criteria above.&#xD;
&#xD;
          -  ≥ 15 years of age.&#xD;
&#xD;
          -  Left ventricular (LV) ejection fraction &gt; 10% as estimated by echocardiography,&#xD;
             contrast ventriculography or radionuclide imaging within the past 90 days.&#xD;
&#xD;
          -  Clinical indication for catheter ablation of VT&#xD;
&#xD;
          -  Intramural ventricular arrhythmias not terminable with standard ablation once enrolled&#xD;
             in the Intramural Needle Ablation study or previous failed ablation within 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
          -  Ability to understand the requirements of the study and sign the informed consent&#xD;
             form.&#xD;
&#xD;
          -  Able and willing to comply with all pre-, post-, and follow-up testing and&#xD;
             requirements.&#xD;
&#xD;
          -  Projected lifespan greater than 1 year.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of MI or CABG within 6 weeks.&#xD;
&#xD;
          -  NYHA Class IV CHF.&#xD;
&#xD;
          -  Patients with idiopathic ventricular arrhythmias defined as VT or PVCs that occur&#xD;
             without evidence of structural heart disease and that are not causing significant&#xD;
             depression of LV function.&#xD;
&#xD;
          -  Women known to be pregnant or to have positive beta-HCG.&#xD;
&#xD;
          -  Definite protruding left ventricular thrombus on pre-ablation echocardiography or&#xD;
             other imaging modalities.&#xD;
&#xD;
          -  Contraindication to heparin&#xD;
&#xD;
          -  Allergy to radiographic contrast dye.&#xD;
&#xD;
          -  Unstable angina that is not due to frequent or incessant VT.&#xD;
&#xD;
          -  Acute non-cardiovascular illness or systemic infection.&#xD;
&#xD;
          -  Thrombocytopenia (platelet count &lt; 50,000 mm3) or coagulopathy.&#xD;
&#xD;
          -  Cardiogenic shock unless it is due to incessant VT.&#xD;
&#xD;
          -  Unable to sign consent.&#xD;
&#xD;
          -  Projected lifespan of &lt; 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 28, 2017</study_first_submitted>
  <study_first_submitted_qc>June 28, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>September 14, 2021</results_first_submitted>
  <results_first_submitted_qc>September 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 12, 2021</results_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>intramural needle ablation</keyword>
  <keyword>ventricular arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT03204981/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intramural Needle Ablation</title>
          <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen failures (no inducible VT or PVCs)</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intramural Needle Ablation</title>
          <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.26" spread="16.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with Ventricular Tachycardia (VT)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with Premature Ventricular Contractions (PVCS)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months</title>
        <description>Number of participants with VT and number of participants with PVCs who had freedom from ventricular arrhythmia at 6 months for participants who had ablation performed using the experimental Needle ablation catheter versus standard ablation catheter.&#xD;
Needle - patient had ablation performed using the experimental Needle ablation catheter.&#xD;
Registry - patient had ablation using a standard ablation catheter and did not need additional ablation using the Needle catheter.</description>
        <time_frame>6 months</time_frame>
        <population>participants analyzed for those with VT and those with PVCs</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With VT</title>
            <description>Participants with Ventricular Tachycardia (VT)</description>
          </group>
          <group group_id="O2">
            <title>Participants With PVCs</title>
            <description>Participants with Premature Ventricular Contractions (PVCS)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Had Freedom From Ventricular Arrhythmia at 6 Months</title>
          <description>Number of participants with VT and number of participants with PVCs who had freedom from ventricular arrhythmia at 6 months for participants who had ablation performed using the experimental Needle ablation catheter versus standard ablation catheter.&#xD;
Needle - patient had ablation performed using the experimental Needle ablation catheter.&#xD;
Registry - patient had ablation using a standard ablation catheter and did not need additional ablation using the Needle catheter.</description>
          <population>participants analyzed for those with VT and those with PVCs</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Needle</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Registry</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Events of Procedural Complications</title>
        <description>Number of events of procedural complications</description>
        <time_frame>at 6 months</time_frame>
        <population>There were 21 participants that experienced a procedural complication event.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramural Needle Ablation</title>
            <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Events of Procedural Complications</title>
          <description>Number of events of procedural complications</description>
          <population>There were 21 participants that experienced a procedural complication event.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Post-ablation Inducibility</title>
        <time_frame>Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramural Needle Ablation</title>
            <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Post-ablation Inducibility</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Termination</title>
        <time_frame>Day 1</time_frame>
        <population>The researchers were only able to capture data on termination times for six patients. Many number of patients did not have termination. Others had termination, but the study team was not able to ascertain the time to termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramural Needle Ablation</title>
            <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Termination</title>
          <population>The researchers were only able to capture data on termination times for six patients. Many number of patients did not have termination. Others had termination, but the study team was not able to ascertain the time to termination.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.16" spread="189.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Duration of Intramural Needle Ablation</title>
        <description>Total duration of intramural needle ablation for patient who had ablation performed using the experimental Needle ablation catheter.</description>
        <time_frame>Day 1</time_frame>
        <population>Data analyzed for participants who had experimental needle ablation.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramural Needle Ablation</title>
            <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Total Duration of Intramural Needle Ablation</title>
          <description>Total duration of intramural needle ablation for patient who had ablation performed using the experimental Needle ablation catheter.</description>
          <population>Data analyzed for participants who had experimental needle ablation.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.14" spread="40.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Intramural Needle Ablations</title>
        <description>Total Number of Intramural Needle Ablations for patient had ablation performed using the experimental Needle ablation catheter.</description>
        <time_frame>Day 1</time_frame>
        <population>Data analyzed for participants who had experimental needle ablation.</population>
        <group_list>
          <group group_id="O1">
            <title>Intramural Needle Ablation</title>
            <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Intramural Needle Ablations</title>
          <description>Total Number of Intramural Needle Ablations for patient had ablation performed using the experimental Needle ablation catheter.</description>
          <population>Data analyzed for participants who had experimental needle ablation.</population>
          <units>ablations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All-cause Mortality</title>
        <time_frame>at 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intramural Needle Ablation</title>
            <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
          </group>
        </group_list>
        <measure>
          <title>All-cause Mortality</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intramural Needle Ablation</title>
          <description>Intramural Needle Ablation: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.&#xD;
Ablation: standard ablation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain with recurrent VT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>CHF</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Complete Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypervolemia with right ventricular failure and increased right sided pressures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>LAA thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericardial effusion with hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Repeated falls</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vasovagal syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy with hyperammonemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure with hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Right Femoral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Apical thrombus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Complete Heart Block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Left bundle branch block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia with intermittent chest pain and dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension with lightheadedness and tremors</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria with UTI and urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Paraphimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Bleed from groin site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Left femoral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Left groin hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sam Cammack</name_or_title>
      <organization>Icahn School of Medicine at Mount Sinai</organization>
      <phone>212-824-8931</phone>
      <email>sam.cammack@mountsinai.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

